We conducted this study to provide in vitro experimental evidence supporting the recent molecular pathological epidemiology studies that suggest tumor PIK3CA mutation status as a biomarker to predict benefits from aspirin therapy for colorectal cancer [9, 12, 13, 21, 38]. Here, PIK3CA is linked to neoplasm.